EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes

Stuti Fernandes, Barbara Hettinger, Lynn Ang, Rodica Pop-Busui

Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 477-493

DOI: 10.1016/j.ecl.2026.04.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Stuti Fernandes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR, USA; Division…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucagon-Like Peptide-1 Receptor Agonists, Mineralocorticoid Receptor Antagonists, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Breakthrough T1D, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose cotransporter inhibitors, glucagon-like peptide 1 receptor agonists and mineralocorticoid receptor blockers have revolutionized type 2 diabetes and by providing substantial cardiovascular and renal protection in this. This article summarizes the data for these newer agents in type 1 diabetes (T1D). Here we also emphasize the need for more long-term studies of these agents in T1D to assess their impact on cardiovascular risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Glucagon-Like Peptide-1 Receptor AgonistsMineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSodium-Glucose Transport ProteinsDiabetic NephropathiesHumans

Stichwörter der Autor:innen

Cardiorenal protectionGlucagon-like peptide 1 receptor agonistsMineralocorticoid receptor antagonistSodium–glucose cotransporter (SGLT) inhibitorsType 1 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsMineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSodium-Glucose Transport Proteins

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR, USA; Division of Endocrinology, Veterans Health Administration, Portland, OR, USA.
  • Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR, USA. Electronic address: busui@ohsu.edu.

Förderung

  • Breakthrough T1D
  • Bayer

Zitieren

APA

Fernandes, S., Hettinger, B., Ang, L., & Pop-Busui, R. (2026). Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 55(3), 477-493. https://doi.org/10.1016/j.ecl.2026.04.007

Vancouver

Fernandes S, Hettinger B, Ang L, Pop-Busui R. Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2026;55(3):477-493. doi:10.1016/j.ecl.2026.04.007

BibTeX
@article{Fernandes2026,
  author = {Fernandes, Stuti and Hettinger, Barbara and Ang, Lynn and Pop-Busui, Rodica},
  title = {Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes},
  journal = {Endocrinology and Metabolism Clinics of North America},
  year = {2026},
  volume = {55},
  number = {3},
  pages = {477--493},
  doi = {10.1016/j.ecl.2026.04.007}
}
Kostenlos starten →